Atlas Trials

Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease

Clinical trial NCT04691661 · RECRUITING

Trial details

NCT number
NCT04691661
Sponsor
Il-Yang Pharm. Co., Ltd.
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Parkinson Disease
Start date
2021-09-09
Primary completion
2025-12-31
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.